The National Institute for Health and Care Excellence has formally paused its re-appraisal of lecanemab, the project page for GID-TA11220 confirming on 29 July 2026 that the evaluation was halted because Eisai and NHS England "have commenced commercial discussions." A near-identical note was added a day later to the parallel project page for donanemab, Eli Lilly's rival drug, which NICE is appraising on the same contested grounds. Neither page now carries an expected publication date; both list it as TBC.
The pause follows a sequence set out on NICE's own timeline: an appeal decision on 20 March 2026 upheld points raised by the manufacturers, prompting NICE on 29 April to commission its Decision Support Unit for a report on the carer-cost and infusion-tariff evidence at the centre of the dispute; a fourth committee meeting followed on 8 July. Three weeks later came the pause notice, rather than the revised final guidance that stakeholders had expected after that meeting.
According to The Pharmaceutical Journal, which obtained comment from all three parties on 29 July 2026, NICE said Eisai "has accepted the independent appraisal committee's assumptions as the basis of commercial discussions," while NHS England said it was "working collaboratively with the manufacturer" at NICE's request. An earlier report, by AOL, described letters NICE sent to the companies stating that the agency "will pause publication of the guidance document to allow this," with hopes of movement by the end of that month; it also noted Eisai has secured US approval for a self-administered, at-home version of lecanemab, with a UK regulatory decision still pending, a change that could in principle lower the infusion costs NICE's committee had flagged as a sticking point.
What has not changed is NICE's final draft guidance from June 2025, which still recommends against routine NHS use of both drugs; that recommendation remains in place unless and until revised guidance is published. Commercial price negotiations between a manufacturer and NHS England are a standard, non-public process that can end without an agreed deal, and neither project page gives a date for when the evaluation will resume.